Medifast(US:MED)2025-04-29 11:21Financial Performance - Q1 2025 revenue reached $116 million[11] - Revenue per active earning coach (AEC) declined by 1.4% year-over-year[8] - The company reported an operating loss of $1.3 million[15] and a loss per share of $0.07[18] - Gross profit margin remained unchanged at 72.8% compared to Q1 2024[5] - The company is debt-free with $165 million in cash and investments as of March 31, 2025[6, 22] Coach and Customer Trends - The number of active earning coaches was 25,400[20] - New coaches grew by double digits year-over-year, marking the highest growth in 3 years[8] - New coach productivity exceeded the same period last year[8] - Almost 50% of coaches have had at least one customer on GLP-1 medications[69] Strategic Initiatives and Future Outlook - The company is targeting $15 million to $20 million in additional savings in 2025[78, 83] - Q2 2025 revenue is projected to be between $85 million and $105 million[90] - Q2 2025 earnings per share are expected to range from a loss of $0.55 to $0.00[90] - The company is expanding its focus to cater to customers in various need-states, including those using GLP-1 medications[24, 31]